Ricerca avanzata

Home > Riviste > Journal of Neurosurgical Sciences > Fascicoli precedenti > Journal of Neurosurgical Sciences 2016 Dicembre;60(4) > Journal of Neurosurgical Sciences 2016 Dicembre;60(4):417-23



Rivista di Neurochirurgia

Indexed/Abstracted in: e-psyche, EMBASE, PubMed/MEDLINE, Neuroscience Citation Index, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,651

Periodicità: Bimestrale

ISSN 0390-5616

Online ISSN 1827-1855


Journal of Neurosurgical Sciences 2016 Dicembre;60(4):417-23


Impact of tumor infiltrating CD63 positive cells on survival in patients with glioblastoma multiforme

Marju KASE 1, 2, Aidi ADAMSON 1, Mikk SARETOK 1, Ave MINAJEVA 1, Markus VARDJA 3, Tõnu JÕGI 3, Toomas ASSER 1, 4, Jana JAAL 1, 3

1 Faculty of Medicine, University of Tartu, Tartu, Estonia; 2 East‑Tallinn Central Hospital, Tallinn, Estonia; 3 Department of Radiotherapy and Oncological Therapy Hematology and Oncology Clinic, Tartu University Hospital, Tartu, Estonia; 4 Department of Neurosurgery, Neurology Clinic, Tartu University Hospital, Tartu, Estonia

BACKGROUND: Glioblastoma multiforme (GBM) is the most aggressive type of brain cancer in adults. It is suggested that tumour microenvironment might influence treatment outcome. The aim of the study was to evaluate the impact of tumor infiltrating CD63 positive (CD63+) inflammatory and immune cells on treatment response and survival of GBM patients.
METHODS: Forty patients were operated and received postoperative radiotherapy (±chemotherapy for recurrent disease). In surgically excised GBM tissues, the number of CD63+ cells per microscopic field was determined and correlated with patient’s survival.
RESULTS: Immunohistochemical parameters were examined by two independent researchers whose results were in good accordance (R=0.8, P<0.001). Median survival time of the study group was 10.0 months (95% CI 9.0-11.0). However, the survival time clearly depended on the number of CD63+ cells in GBM tissue (log rank test, P=0.003). Median survival times for patients with low (< median) and high (≥ median) number of CD63+ cells were 9.0 months (95% CI 8.1-9.9) and 12.0 months (95% CI 8.5-15.5) respectively. In multivariate analysis, the number of CD63+ cells emerged as a significant independent predictor for overall survival (HR 2.4, 95% CI 1.2-5.1, P=0.02).
CONCLUSIONS: The higher number of tumor infiltrating CD63+ inflammatory and immune cells in GBM tissue corresponded to better survival after postoperative radiotherapy. Since radiotherapy is one of the cornerstones of adjuvant treatment in GBM, further studies are needed for better understanding of GBM biology.

lingua: Inglese


inizio pagina